SANTA BARBARA, Calif.--(BUSINESS WIRE)--Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetic market, announced today that it has received approval from the U.S. Food and Drug Administration for an amendment to the Company’s MemoryGel™ silicone gel-filled breast implant post-approval study (PAS) protocol. The PAS protocol amendment addresses patient enrollment.
